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Objective To characterize the serum kinetics of prostate 
specific antigen {PSA) after visual laser ablation of the 
prostate (VLAP).
Patients and methods The PSA ve of 45 patients 
were measured at 24 h and at 1, 4, 12, 26 and 52 
weeks after VLAP and the changes assessed in relation 
to symptom scores, urinary flow rates and prostate 
size.
Results After an initial rise immmediately after VLAP, 
the serum PSA level declined. At 24 h, the PSA value 
reached a mean level 23 times higher than the PSA 
level before VLAP and then took a mean of 78 days 
to reach a new baseline. The mean decrease of the 
subsequent baseline value relative to that before treat­
ment was 1.7 ng/mL. The prostatic size and energy 
applied correlated positively with the rise in PSA 24 h 
after VLAP. The rise in maximal urinary llow after 
VLAP, the decrease in the symptom score and residual 
urine volume did not correlate with the rise in PSA 
level 24 h after VLAP or with the time to reach a 
value halfway between the level at 24 h and the new 
baseline value.
Conclusions The pattern of the increase in serum PSA 
level and decline after VLAP was not predictive of the 
clinical outcome of therapy.
Keywords Prostate specific antigen, benign prostatic 
enlargement, laser treatment
Introduction
PSA is secreted by prostatic epithelial cells into the 
lumina of the prostate ducts; the concentration of PSA 
in prostatic secretions is about 106 of that in serum [1]. as it is after TURP [7],
:ic cancer are present. After VLAP, prostatic 
cancer can develop in the remaining prostatic tissue. 
Because the heterogenicity of the TRUS image increases 
after VLAP, the predictive value of TRUS is decreased,
Normal prostatic epithelial cells are separated from the 
capillary and lymphatic system by an intact basal cell 
layer and basement membrane [2], When the basal 
membrane of the prostatic epithelium is disrupted, PSA 
in the lumen can leak into the serum and increase the 
serum PSA concentration, invasive treatments like TURP 
cause a rapid rise in the level of serum PSA [3-6]; acini 
rich in PSA are transected during the operation for BPE 
and the enzymes are released into the fossa where they 
are absorbed by the irrigating fluid. After an invasive 
treatment for BPE, the PSA level increases and the value 
cannot be used to differentiate reliably between BPE and 
prostatic cancer until the PSA level attains a new
prostateDuring this post-operative 
cancer can be detected largely by determining 
PSA level and by a DRE. The interpretation of 
serum PSA levels after VLAP is only possible if the 
kinetics of serum PSA are known. Moreover, an aware­
ness of the incidence of false-positive findings from PSA 
after VLAP could reduce unnecessary anxiety in 
patient, and the need for prostate biopsies.
The serum kinetics of PSA after VLAP for BPE have 
not been characterized sufficiently and the potential 
prognostic significance for the clinical outcome of vari­
ables describing the changes in PSA after VLAP are
unclear. To address we evaluated the
baseline value. In a patient who is considered a candidate changes in the serum PSA levels of patients with jJ
for visual laser ablation of the prostate (VLAP), the 
presence of prostatic carcinoma should be excluded, as 
during VLAP no tissue is obtained for histopathological 
examination and consequently it is uncertain whether
after they had been treated with VLAP.
Accepted for publication 22 July 1996
Patients and methods
The study group consisted of 45 patients, all considered 
clinically to have BPE as assessed by a symptom score
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UPSS), urollowmetry, a l)RK and (he appearance of the 
prostate on TRUS. If I heir I’SA level was >4 ng/mL
before treatment , biopsies were taken to exclude prostate After an initial rise caused by VLAP, the serum PSA 
cancer. All patients underwent elective VLAP
side-firing libre; use of and outcome with these
level declined (Table 1); the times at which PSA was
varied slightly from the intended times. The
devices has been reported previously |S |. The mean (so) similarity in the values at 12 and 26 weeks suggests
prostate volume before treatment was SO (15) mL and that the value attained a new baseline and was no
mean (s d ) energy delivered during VLAP was 47 longer decreasing. This was confirmed by measurements
(16) kj. All patients were managed post-operatively taken in six patients at 52 weeks, where only two
with a SLinranubie catheter (median duration 12 davx. xhnwf»H a sliwht increase in PSA level compared with thesuprap c ys,
5-58). Each patient had serial determinations of values at 12 and 26 weeks, and lor all six the increase
PSA before VLAP, at 24 h anti 1 week after VLAP, and 
on at least at two of 4, 12, 26 and 52 weeks after
VI, AI the Tandem-K PSA assay
CA,
(zero dose+* * sn) was 
For statistical an
were replaced
of <
was
of
e
signed rank test). Analysis
residual errors f 
best by a double-
at values were
ial model and the model
'\s:
W1 W C x exp (exp (A — B x (t — 1)))
a nominal value of where £ denotes the time in days after VLAP with £ ^  1,
0.5 . The PSA measurements after VLAP were C is the asymptotic value of the baseline reached after 
VLAP, A determines the value at £ =  1 and B is the rate 
of the decrease in PSA 24 h after VLAP. The rate of 
decrease is greater in the first few days after VLAP than 
in the succeeding weeks and thus the ‘half-life’ is not 
optimal parameters quickly. To describe constant but increases steadily. The parameters A, B and 
the PSA change in each patient, the following variables C were fitted for each of the 45 patients using a weighting 
were determined: (i) the absolute rise of PSA 24 h after inversely proportional to the square of the PSA values
used to obtain the best lit with a mathematical model 
that described accurately the decrease in serum PSA. 
For each patient, values were fitted using the Marquurdt 
non-linear regression method, chosen because it usually
?d with the pre-operative value (ÀPSA);
(ii) the relative rise of PSA 24 h after surgery compared ?
me weighting for values of 0.5 ng/mL as for 
. Figure 1 shows the mean PSA value after
w i pre-operative value (APSAr); (iii) the time for VLAP in all 45 patients with an example of a double-
PSA level to reach a value hallway between the exponential curve fitted to the values. The fitted estimates
va at 24 h after VLAP and the
•rence
new (asymptotic) 
*en the pre-baseline ('172); (iv) 
operative PSA value and the value at the new baseline
and; (v) the time for the PSA level to reach a
new baseline (T10%).value 10"'m of
of the parameters were used to calculate different charac­
teristics of the fitted curve.
The mean (sn) PSA level 24 h after VLAP was 103 
(59) ng/mL, was 23 (si) 15) times greater than 
before VLAP. The mean (sd) value of T/2
Correlations between these variables and various other was 5.6 (2.3) days and the mean (sd ) value of T10% was
clinical indices were determined using Pearson’s method
rization). The 
presence of a
78 (49) days; the mean (sd ) level of the new baseline 
was 1.7 (2.7) ng/mL below the level before VLAP.
Table 2 shows the relationship between the character­
istics of the PSA curves and the clinical features of the 
presence of post-operative urinary infection was ana- patients. In patients with a large prostate, the rise in 
Ivsed
(or Spearman's, for the duration of ei 
relationship of these variables with
laser-induced cav as seen on TRUS and
Student's (-tests for two samples. PSA level was generally greater and the new baseline
Table 1 Serum PSA of 45 palimi,'; More and after VI.AP
PSA lew! Hefan
VLAP
Mean
n
6.2
< 1.0.H.5
15
Alter
i t  IiJfcs*
107.8
9.7290
45
After (weeks)
I
Î0.9
1.5-92.0
■IS
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<1.0-31.0
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Fig. 1. The mean (so) change in PSA values after VLAP ( A ) in 45 
patients, as determined from the original measurements, with the 
fitted curve. (V), before VLAP.
was ret sooner. The energy given during VLAP 
correlated moderately with the rise in PSA 24 h after 
VLAP but there was no significant correlation between 
the characteristics of the PSA curves i 3 rise m
VLAP (P — 0.01). The duration of suprapubic catheteriz­
ation was negatively correlated with the relative rise of 
PSA at 24 h after VLAP, T/2, the new baseline and with 
T10%. In patients where there was a laser-induced cavity, 
as detected using TRUS 26 weeks after VLAP, there was 
a significantly higher mean value lor PSAr at 24 h, T/ 
and TU)%. In patients with a urinary infection post- 
operatively, the mean T/2 was significantly lower. At 
26 weeks after VLAP, the serum PSA level was >
10.0 and than re VLAP in two
patients; these patients underwent TRUS-guided prostatic 
biopsies, taking three cores from the right and the left
apex. Theslant from base and
histopathological examination revealed focal invasion of
white blood cells a normal
pattern of prostatic acini.
Discussion
The fitted parameters from the curve for each patient
were used for am I n* than the
maximum urinary flow rate after VLAP, the decrease in 
the IPSS or the decrease in residual urine volume. There 
was a weak correlation (r = 0.45) between the decline 
in serum PSA level at the new baseline compared with values, thus partly correcting for any variation in the 
the PSA value before VLAP and with the reduction in actual sampling time, and explaining the differences in 
prostate volume as measured with TRUS 26 weeks after the increase in PSA level at 24 h after VLAP between
Table 2 Relationships between parameters describing the changing PSA level after VLAP and the clinical parameters
¿IPS A A PSAr T/2 APSAb Turn
Pearson correlation coefficients and P values 
Prostate volume 0.40 - 0.31 -0.25 -0.10 — 0.46
P 0.006 0.04 ns ns 0.002
Energy 0.34 — 0.06 0.00 0.16 -0.03
P 0.02 ns ns ns ns
Energy/volume -0.05 0.24 0.2 1 0.20 0.36
P ns ns ns ns 0.01
AVolume
P
Spearman correlation coefficients and P values
SPC W  1 4 * 4  \ / ..0.52 -0.38
0.45
0.01
 ^ 0,15 MCI *  /  *  i f  ■ j l
P ns 0.0? 0.01 IIS <0.001
Means (so) and P values accordinu to Student's I-tests 
Cavity 
Yes (n — 25) 109 (69) 27 (17) 6.1 (2.6) 1.7 (2.4) 9 5 (56)
No (»=18) 97 (46) 17 (9) 4.6 (1.7) 1.5 ( Î.2) 52 (21)
P ns 0.04 0.04 ns 0.004
Infection
Yes (« = 21) 9 1 (61) 22(12) 4.K (l.K) 1 5 Í 5 > )l♦ . '  \ ♦ a M  f 6 7 ( 4 3 )
No (» = 24) 1 14 (57) 24 (IK) 6.2 (2.6) 1.9 (3.2) SS (52)
P ns ns 0.05 ns ns
APSA, PSA at 24 h after VLAP minus the initial value. APSAr, PSA level 24 h after VLAP relative to the initial value. T/2, the time to 
reach a PSA level halfway between the value at 24 h and at the new baseline. APSAb, the initial PSA level minus that at the new 
baseline. T10%, the time for the PSA level to reach a value within 10% of the new baseline. Unergy, the amount of energy delivered to the 
prostate during VLAP. A Volume, the reduction in prostate volume at 26 weeks after VI,AP. SPC, duration of suprapubic catheterization. 
Cavity, the presence of a cavity on TRUS. Infection, post-operative urinary infection. ns-=not significant (/*>0.05)
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the model and the values in Table 1. The 2 3-fold increase 
24 h after VLAP indicates that the tissue was extensively 
damaged. This rise is comparable with the 14-fold (sd 
4) increase of PSA 24 h after transurethral ultrasound- 
guided laser-induced prostatectomy (TULIP) found by 
Bosch et al. [9]. However, it is much higher than the 
5.9ng/mL increase 18-24 h after TURP reported by
Oesterling et al. [3]. Using the Yang assay, Stamey et a l remains in the prostate for a long time after treatment
4] reported a 53-fold rise in PSA concentration in six with high-intensity focused ultrasound, transurethral
patients immediately alter I IJRP lor BPE; Vesey et a l [5] needle ablation and transurethral microwave thermo-
eported that PSA levels rose ninefold immediately after therapy, the time necessary for serum PSA levels to
__________ — . . . j  —  -___  _  ^  4 -  —
prostatectomy than after TURP. A possible explanation 
could be the altered architecture of the prostate after 
VLAP, with necrotic tissue remaining in situ rather than 
being immediately resected as in TURP. The lower level 
of PSA at the new baseline after VLAP compared with 
the level before treatment may reflect the ablation of 
PSA-producing tissue during VLAP. As necrotic tissue
r
T Price et a l [6 3ls at 1, 3, 5 reach a new baseline after these procedures should be
ind 4-2 days after TURP; PSA levels were elevated on comparable with that after VLAP. 
days 1, 3 and 5 among patients with BPE and gradually In the present study, the T10% of a high proportion of
decreased to below the baseline value by 42 days. the patients was reached within 4 months; if the PSA
rise of PSA alter TURP with the rise after level does not decline to a new baseline 4 months after
laser ablation ol the prostate, Kabalin et al, [10] reported VLAP, further management of the patient will depend
similar peak levels alter both procedures; however, the on the decisions of the individual clinician and such
peak value occurred immediately after TURP, in the patients may represent a high-risk group for prostate
ecovery room, but 24 h alter laser ablation. The differ- cancer. Because serum PSA values vary within anr
enee TURP and VLAP in the time taken to individual, measurements must be repeated to confirm
reach the peak PSA level, and the different impact on any suspicious increase. We recommend that biopsies
prostatic tissue, might explain the different responses in are taken when the PSA is consistently and significantly
PSA level post-operatively reported by these authors. above the pre-operative level during this period. An
According to Stamey et al. [12] and Vesey et al. [5], a alternative approach is to keep these patients under
dramatic rise in serum PSA immediately after TURP prospective review, using DRE, PSA measurements and
implies BPE rather than prostate cancer, as they found TRUS at 6-monthly intervals. If a new baseline PSA
insignificant or much smaller increases in serum PSA in value is reached and the serum PSA starts to rise again
the latter after TURP. Vesey et a l [5] suggested that this after VLAP, the percentage PSA increase with time (PSA
difference could be caused by a more easily extractable slope) may be used to distinguish patients with carci-
store of PSA in the dilated acinar spaces of hyperplastic noma. Oesterling et al. [13] found that a rise of >20%
tissue, containing pooled prostatic secretions rich in PSA. per year indicated carcinoma. Accordingly, Feneley et al.
In the present study, the decrease in the PSA level [7] reported that serial measurements of PSA in patients
after VLAP followed a double-exponential curve. In this with incidental carcinoma found after TURP allowed the
model, the ‘half-lile’ is not constant but increases steadily, disease activity to be monitored and a PSA slope 20%
which could be explained by an initial sharp decline in per year was the most accurate marker to predict biopsy-
PSA level caused by the disappearance of the sequestered proven residual disease. Although no malignancy was
PSA that leaked into the blood during VLAP, after which found in the present patients with increasing PSA levels
there was less but persistent leakage of PSA from dam- one year after VLAP, the PSA slope might be helpful in
aged prostatic tissue. The half-life of serum PSA has diagnosing prostate carcinoma after VLAP.
been calculated by Oesterling et a l 111] to be 3.15 days, In conclusion, because of the effects of VLAP on serum
using the Tandem-R PSA assay, and by Stamey et al. PSA it is not useful to measure PSA for the 4 months
12] to be 2.2 days, using the Pros-Check PSA assay. after VLAP. The kinetics of serum PSA level after VLAP
The ‘half-life’ of 5.6 days 24 h after VLAP is considerably provided no useful information to predict the clinical
longer and supports the hypothesis that the decrease in outcome.
PSA after VLAP is by damaged prostatic 
The attainment of a new (lower) mean (sd) 
baseline at 78 (49) days after VLAP is comparable with References
that found by Bosch et al. [9] after TULIP. However, it 
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Objective To characterize the serum kinetics of prostate 
specific antigen {PSA) after visual laser ablation of the 
prostate (VLAP).
Patients and methods The PSA ve of 45 patients 
were measured at 24 h and at 1, 4, 12, 26 and 52 
weeks after VLAP and the changes assessed in relation 
to symptom scores, urinary How rates and prostate 
size.
Results After an initial rise immmediately after VLAP, 
the serum PSA level declined. At 24 h, the PSA value 
reached a mean level 23 times higher than the PSA 
level before VLAP and then took a mean of 78 days 
to reach a new baseline. The mean decrease of the 
subsequent baseline value relative to that before treat­
ment was 1.7 ng/mL. The prostatic size and energy 
applied correlated positively with the rise in PSA 24 h 
after VLAP. The rise in maximal urinary How after 
VLAP, the decrease in the symptom score and residual 
urine volume did not correlate with the rise in PSA 
level 24 h after VLAP or with the time to reach a 
value halfway between the level at 24 h and the new 
baseline value.
Conclusions The pattern of the increase in serum PSA 
level and decline after VLAP was not predictive of the 
clinical outcome of therapy.
Keywords Prostate specific antigen, benign prostatic 
enlargement, laser treatment
Introduction
PSA is secreted by prostatic epithelial cells into the 
lumina of the prostate ducts; the concentration of PSA 
in prostatic secretions is about 106 of that in serum [1]. as it is after TURP [7],
:ic cancer are present. After VLAP, prostatic 
cancer can develop in the remaining prostatic tissue. 
Because the heterogenicity of the TRUS image increases 
after VLAP, the predictive value of TRUS is decreased,
Normal prostatic epithelial cells are separated from the 
capillary and lymphatic system by an intact basal cell 
layer and basement membrane [2], When the basal 
membrane of the prostatic epithelium is disrupted, PSA 
in the lumen can leak into the serum and increase the 
serum PSA concentration, invasive treatments like TURP 
cause a rapid rise in the level of serum PSA [3—6]; acini 
rich in PSA are transected during the operation for BPE 
and the enzymes are released into the fossa where they 
are absorbed by the irrigating fluid. After an invasive 
treatment for BPE, the PSA level increases and the value 
cannot be used to differentiate reliably between BPE and 
prostatic cancer until the PSA level attains a new
prostateDuring this post-operative 
cancer can be detected largely by determining 
PSA level and by a DRE. The interpretation of 
serum PSA levels after VLAP is only possible if the 
kinetics of serum PSA are known. Moreover, an aware­
ness of the incidence of false-positive findings from PSA 
after VLAP could reduce unnecessary anxiety in 
patient, and the need for prostate biopsies.
The serum kinetics of PSA after VLAP for BPE have 
not been characterized sufficiently and the potential 
prognostic significance for the clinical outcome of vari­
ables describing the changes in PSA after VLAP are
unclear. To address we evaluated the
baseline value. In a patient who is considered a candidate changes in the serum PSA levels of patients with jJ
for visual laser ablation of the prostate (VLAP), the 
presence of prostatic carcinoma should be excluded, as 
during VLAP no tissue is obtained for histopathological 
examination and consequently it is uncertain whether
after they had been treated with VLAP.
Accepted for publication 22 July 1996
Patients and methods
The study group consisted of 45 patients, all considered 
clinically to have BPE as assessed by a symptom score
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UPSS), urollowmetry, a l)RK and (he appearance of the 
prostate on TRUS. If their PSA level was >4 ng/mL
before treatment , biopsies were taken to exclude prostate After an initial rise caused by VLAP, the serum PSA 
cancer. All patients underwent elective VLAP
side-firing libre; use of and outcome with these
level declined (Table 1); the times at which PSA was
varied slightly from the intended times. The
devices has been reported previously |S|. The mean (si>) similarity in the values at 12 and 26 weeks suggests
prostate volume before treatment was SO (15) mL and that the value attained a new baseline and was no
mean (sd) energy delivered during VLAP was 47 longer decreasing. This was confirmed by measurements
(16) kj. All patients were managed post-operatively taken in six patients at 52 weeks, where only two
with a sunranubie catheter (median duration 12 davs. shnw(*r1 a slight increase in PSA level compared with thep p c y ,
5-58). Each patient had serial determinations of values at 12 and 26 weeks, and lor all six the increase
PSA before VLAP, at 24 h anti 1 week after VLAP, and 
on at least at two of 4, 12, 26 and 52 weeks after
VI, AI the Tandem-K PSA assay
OA,
(zero dose I * sn) was 
For statistical an
were replaced
of <
was
of
e
signed rank test). Analysis
residual errors f 
best by a double-
at values were
ial model and the model
'\s;
W1 w C x exp (exp (A —B x (t — 1)))
a nominal value of where £ denotes the time in days after VLAP with £ ^  1,
0.5 . The PSA measurements after VLAP were C is the asymptotic value of the baseline reached after 
VLAP, A determines the value at £ =  1 and B is the rate 
of the decrease in PSA 24 h after VLAP. The rate of 
decrease is greater in the first few days after VLAP than 
in the succeeding weeks and thus the ‘half-life’ is not 
optimal parameters quickly. To describe constant but increases steadily. The parameters A, B and 
the PSA change in each patient, the following variables C were fitted for each of the 45 patients using a weighting 
were determined: (i) the absolute rise of PSA 24 h after inversely proportional to the square of the PSA values
used to obtain the best lit with a mathematical model 
that described accurately the decrease in serum PSA. 
For each patient, values were fitted using the Marquurdt 
non-linear regression method, chosen because it usually
?d with the pre-operative value (ÀPSA);
(ii) the relative rise of PSA 24 h after surgery compared ?
me weighting for values of 0.5 ng/mL as for 
. Figure 1 shows the mean PSA value after
w i pre-operative value (APSAr); (iii) the time lor VLAP in all 45 patients with an example of a double-
PSA level to reach a value hallway between the exponential curve fitted to the values. The fitted estimates
v a at 24 h after VLAP and the
•rence
new (asymptotic) 
*en the pre-baseline ('172); (iv) 
operative PSA value and the value at the new baseline
and; (v) the time for the PSA level to reach a
new baseline (T10%).value K)"'m of
of the parameters were used to calculate different charac­
teristics of the fitted curve.
The mean (sn) PSA level 24 h after VLAP was 103 
(59) ng/mL, was 23 (sd 15) times greater than 
before VLAP. The mean (sd) value of T/2
Correlations between these variables and various other was 5.6 (2.3) days and the mean (sd) value of T10% was
clinical indices were determined using Pearson’s method
rization). The 
presence of a
78 (49) days; the mean (sd ) level of the new baseline 
was 1.7 (2.7) ng/mL below the level before VLAP.
Table 2 shows the relationship between the character­
istics of the PSA curves and the clinical features of the 
presence of post-operative urinary infection was ana- patients. In patients with a large prostate, the rise in 
Ivsed
(or Spearman's, for the duration of ei 
relationship of these variables with
laser-induced eav as seen on TRUS and
Student's (-tests for two samples. PSA level was generally greater and the new baseline
Table 1 Serum PSA of 45 palimi,'; More and after VI.At1
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VLAP
Mean
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lïg. 1. The mean (so) change in PSA values after VLAP ( A ) in 45 
patients, as determined from the original measurements, with the 
fitted curve. (V), before VLAP.
was ret sooner. The energy given during VLAP 
correlated moderately with the rise in PSA 24 h after 
VLAP but there was no significant correlation between 
the characteristics of the PSA curves i 3 rise m
VLAP (P — 0.01). The duration of suprapubic catheteriz­
ation was negatively correlated with the relative rise of 
PSA at 24 h after VLAP, T/2, the new baseline and with 
TK)%. In patients where there was a laser-induced cavity, 
as detected using TRUS 26 weeks after VLAP, there was 
a significantly higher mean value lor PSAr at 24 h, T/ 
and TU)%. In patients with a urinary infection post- 
operatively, the mean T/2 was significantly lower. At 
26 weeks after VLAP, the serum PSA level was >
10.0 and than re VLAP in two
patients; these patients underwent TRUS-guided prostatic 
biopsies, taking three cores from the right and the left
apex. Theslant from base and
histopathologieal examination revealed focal invasion of
white blood cells a normal
pattern of prostatic acini.
Discussion
The fitted parameters from the curve for each patient
were used for am I n* than the
maximum urinary flow rate after VLAP, the decrease in 
the IPSS or the decrease in residual urine volume. There 
was a weak correlation (r = 0.45) between the decline 
in serum PSA level at the new baseline compared with values, thus partly correcting for any variation in the 
the PSA value before VLAP and with the reduction in actual sampling time, and explaining the differences in 
prostate volume as measured with TRUS 26 weeks after the increase in PSA level at 24 h after VLAP between
Table 2 Relationships between parameters describing the changing PSA level after VLAP and the clinical parameters
APSA APSAr T/2 APSAb Turn
Pearson correlation coefficients and P values 
Prostate volume 0.40 -  0.31 — 0.25 -0.10 — 0.46
P 0.006 0.04 ns ns 0.002
Energy 0.34 — 0.06 0.00 0.16 -0.03
P 0.02 ns ns ns ns
Energy/volume -0.05 0.24 0.2 1 0.20 0.36
P ns ns ns ns 0.01
AVolume
P
Spearman correlation coefficients and P values
SPC W  1 4 * 4  \ / ..0.52 -0.38
0.45
0.01
 ^ 0,15 MCI *  /  *  i f  ■ j l
P ns 0.0? 0.01 IIS <0.001
Means (so) and P values accordinu to Student's I-tests 
Cavity 
Yes (n — 25) 109 (69) 27 (17) 6.1 (2.6) 1.7 (2.4) 9 5 (56)
No (»=18) 97 (46) 17 (9) 4.6 (1.7) 1.5 ( Î.2) 52 (21)
P ns 0.04 0.04 ns 0.004
Infection
Yes (« = 21) 9 1 (hi) 22(12) 4.K (l.H) 1 5 Í 5 > )l ♦ . ’ \♦ a M  f 6 7 ( 4 3 )
No (» = 24) 1 14 (57) 24 (IK) 6.2 (2.6) 1.9 (3.2) HH (52)
P ns ns 0.05 ns ns
APSA, PSA at 24 h after VLAP minus the initial value. APSAr, PSA level 24 h after VLAP relative to the initial value. '172, the time to 
reach a PSA level halfway between the value at 24 h and at the new baseline. APSAb, the initial PSA level minus that al the new 
baseline. T10%, the time for the PSA level to reach a value within 10% of the new baseline. Unergy, the amount of energy delivered to the 
prostate during VLAP. A Volume, the reduction in prostate volume at 26 weeks after VI,AP. SPC, duration of suprapubic catheterization. 
Cavity, the presence of a cavity on TRUS. Infection, post-operative urinary infection, ns« not significant (/’>().05)
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the model and the values in Table 1. The 2 3-fold increase 
24 h after VLAP indicates that the tissue was extensively 
damaged. This rise is comparable with the 14-fold (sd 
4) increase of PSA 24 h after transurethral ultrasound- 
guided laser-induced prostatectomy (TULIP) found by 
Bosch et al. [9]. However, it is much higher than the 
5.9ng/mL increase 18-24 h after TURP reported by
Oesterling et al. [3]. Using the Yang assay, Stamey et al remains in the prostate for a long time after treatment
4] reported a 53-fold rise in PSA concentration in six with high-intensity focused ultrasound, transurethral
patients immediately alter I lIRP lor BPE; Vesey et al [5] needle ablation and transurethral microwave thermo-
eported that PSA levels rose ninefold immediately after therapy, the time necessary for serum PSA levels to
__________ . — . . . j  —  -___  _  ^  4 -  —
prostatectomy than after TURP. A possible explanation 
could be the altered architecture of the prostate after 
VLAP, with necrotic tissue remaining in situ rather than 
being immediately resected as in TURP. The lower level 
of PSA at the new baseline after VLAP compared with 
the level before treatment may reflect the ablation of 
PSA-producing tissue during VLAP. As necrotic tissue
r
T Price el al [6 3ls at 1, 3, 5 reach a new baseline after these procedures should be
ind 4-2 days after TURP; PSA levels were elevated on comparable with that after VLAP. 
days 1, 3 and 5 among patients with BPE and gradually In the present study, the T10% of a high proportion of
decreased to below the baseline value by 42 days. the patients was reached within 4 months; if the PSA
rise of PSA alter TURP with the rise after level does not decline to a new baseline 4 months after
laser ablation ol the prostate, Kabalin et al. [10] reported VLAP, further management of the patient will depend
similar peak levels after both procedures; however, the on the decisions of the individual clinician and such
peak value occurred immediately after TURP, in the patients may represent a high-risk group for prostate
ecovery room, but 24 h alter laser ablation. The differ- cancer. Because serum PSA values vary within anr
enee TURP and VLAP in the time taken to individual, measurements must be repeated to confirm
reach the peak PSA level, and the different impact on any suspicious increase. We recommend that biopsies
prostatic tissue, might explain the different responses in are taken when the PSA is consistently and significantly
PSA level post-operatively reported by these authors. above the pre-operative level during this period. An
According to Stamey et al. [12] and Vesey et al [5], a alternative approach is to keep these patients under
dramatic rise in serum PSA immediately after TURP prospective review, using DRE, PSA measurements and
implies BPE rather than prostate cancer, as they found TRUS at 6-monthly intervals. If a new baseline PSA
insignificant or much smaller increases in serum PSA in value is reached and the serum PSA starts to rise again
the latter after TURP. Vesey et al [5] suggested that this after VLAP, the percentage PSA increase with time (PSA
difference could be caused by a more easily extractable slope) may be used to distinguish patients with carci-
store of PSA in the dilated acinar spaces of hyperplastic noma. Oesterling et al. [13] found that a rise of >20%
tissue, containing pooled prostatic secretions rich in PSA. per year indicated carcinoma. Accordingly, Feneley et al.
In the present study, the decrease in the PSA level [7] reported that serial measurements of PSA in patients
after VLAP followed a double-exponential curve. In this with incidental carcinoma found after TURP allowed the
model, the ‘half-life’ is not constant but increases steadily, disease activity to be monitored and a PSA slope 20%
which could be explained by an initial sharp decline in per year was the most accurate marker to predict biopsy-
PSA level caused by the disappearance of the sequestered proven residual disease. Although no malignancy was
PSA that leaked into the blood during VLAP, after which found in the present patients with increasing PSA levels
there was less but persistent leakage of PSA from dam- one year after VLAP, the PSA slope might be helpful in
aged prostatic tissue. The half-life of serum PSA has diagnosing prostate carcinoma after VLAP.
been calculated by Oesterling et al. I'll] to be 3.15 days, In conclusion, because of the effects of VLAP on serum
using the Tandem-R PSA assay, and by Stamey et al. PSA it is not useful to measure PSA for the 4 months
12] to be 2.2 days, using the Pros-Check PSA assay. after VLAP. The kinetics of serum PSA level after VLAP
The‘half-life’ of 5.6 days 24 h after VLAP is considerably provided no useful information to predict the clinical
longer and supports the hypothesis that the decrease in outcome.
PSA after VLAP is by damaged prostatic 
The attainment of a new (lower) mean (sd) 
baseline at 78 (49) days after VLAP is comparable with References
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is considerably longer than the median time required for 
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